This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-17. Anything still debated is marked as such rather than presented as settled.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
GlcNAc/NS(6S)-GlcA-GlcNS(3S,6S)-IdoA(2S)-GlcNS(6S) The conformational change in AT on heparin-binding mediates its inhibition of factor Xa. For thrombin inhibition, however, thrombin must also bind to the heparin polymer at a site proximal to the pentasaccharide. The highly negative charge density of heparin contributes to its very strong electrostatic interaction with thrombin. The formation of a ternary complex between AT, thrombin, and heparin results in the inactivation of thrombin. For this reason, heparin's activity against thrombin is size-dependent, with the ternary complex requiring at least 18 saccharide units for efficient formation. In contrast, antifactor Xa activity via AT requires only the pentasaccharide-binding site. This size difference has led to the development of low-molecular-weight heparins (LMWHs) and fondaparinux as anticoagulants. Fondaparinux targets anti-factor Xa activity rather than inhibiting thrombin activity, to facilitate a more subtle regulation of coagulation and an improved therapeutic index. It is a synthetic pentasaccharide, whose chemical structure is almost identical to the AT binding pentasaccharide sequence that can be found within polymeric heparin and heparan sulfate. With LMWH and fondaparinux, the risk of osteoporosis and heparin-induced thrombocytopenia (HIT) is reduced. Monitoring of the activated partial thromboplastin time is also not required and does not reflect the anticoagulant effect, as APTT is insensitive to alterations in factor Xa.
Basic hydrolysis of esters, known as saponification, is not an equilibrium process; a full equivalent of base is consumed in the reaction, which produces one equivalent of alcohol and one equivalent of a carboxylate salt. The saponification of esters of fatty acids is an industrially important process, used in the production of soap. Esterification is a reversible reaction. Esters undergo hydrolysis under acidic and basic conditions. Under acidic conditions, the reaction is the reverse reaction of the Fischer esterification. Under basic conditions, hydroxide acts as a nucleophile, while an alkoxide is the leaving group. This reaction, saponification, is the basis of soap making.
Ethanol is also known chemically as alcohol, ethyl alcohol, or drinking alcohol. It is a simple alcohol with a molecular formula of C2H6O and a molecular weight of 46.0684 g/mol. The molecular formula of ethanol may also be written as CH3−CH2−OH or as C2H5−OH. The latter can also be thought of as an ethyl group linked to a hydroxyl (alcohol) group and can be abbreviated as EtOH. Ethanol is a volatile, flammable, colorless liquid with a slight characteristic odor. Aside from its use as a psychoactive and recreational substance, ethanol is also commonly used as an antiseptic and disinfectant, a chemical and medicinal solvent, and a fuel.
== In vitro activity == Oritavancin shares certain properties with other members of the glycopeptide class of antibiotics, which includes vancomycin, the current standard of care for serious Gram-positive infections in the United States and Europe. It possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci. Oritavancin has potential use as a therapy for exposure to Bacillus anthracis, the Gram-positive bacterium that causes anthrax, having demonstrated efficacy in a mouse model both before and after exposure to the bacterium. Oritavancin demonstrates in vitro activity against both the planktonic and biofilmstates of staphylococci associated with prosthetic joint infection (PJI), albeit with increased minimum biofilm bactericidal concentration (MBBC) compared to Minimum inhibitory concentrations (MIC) values. Moreover oritavancin has demonstrated activity against in vitro to vancomycin-susceptible enterococci (VSE) and vancomycin-resistant enterococci (VRE) in both planktonic and biofilm states.
Mutations in the OTC gene can cause Ornithine transcarbamylase deficiency. It is classified as a urea cycle disorder due to the fact that without proper OTC function ammonia starts to accumulate in the blood. Accumulation of ammonia in the blood is known as hyperammonemia. Although toxic in excess, ammonia is a nitrogen source for the body. Therefore increased ammonia will also increase levels of the nitrogen-containing non-essential amino acids glutamate, glutamine, and alanine. Levels of carbamoyl phosphate (CP) will begin to drop as urea nitrogen levels in the blood decrease. This will cause CP to be diverted to the uridine monophosphate synthetic pathway. Orotic acid is a product of this pathway. Increased levels of orotic acid in urine can be an indicator that a patient is suffering from a disorder linked to hyperammonemia. OTC deficiency manifests in both early and late onset forms.
Sources: en.wikipedia.org
where p0 is called total pressure, and q is dynamic pressure. Many authors refer to the pressure p as static pressure to distinguish it from total pressure p0 and dynamic pressure q. In Aerodynamics, L.J. Clancy writes: "To distinguish it from the total and dynamic pressures, the actual pressure of the fluid, which is associated not with its motion but with its state, is often referred to as the static pressure, but where the term pressure alone is used it refers to this static pressure." The simplified form of Bernoulli's equation can be summarized in the following memorable word equation:
The most common Quechua dialect is Southern Quechua. The Kichwa people of Ecuador speak the Kichwa dialect; in Colombia, the Inga people speak Inga Kichwa. The Quechua word for a Quechua speaker is runa or nuna ("person"); the plural is runakuna or nunakuna ("people"). "Quechua speakers call themselves Runa -- simply translated, "the people". Quechua became Peru's second official language in 1969 under the military dictatorship of Juan Velasco Alvarado. There have been later tendencies toward nation-building among Quechua speakers, particularly in Ecuador (Kichwa) but also in Bolivia, where there are only slight linguistic differences from the Peruvian version. An indication of this effort is the umbrella organization of the Kichwa people in Ecuador, ECUARUNARI (Ecuador Runakunapak Rikcharimuy).
=== Laboratory synthesis === Formaldehyde was discovered in 1859 by the Russian chemist Aleksandr Butlerov (1828–1886) when he tried to synthesize methanediol ("methylene glycol") from iodomethane and silver oxalate. In his paper, Butlerov called formaldehyde "dioxymethylen" (methylene dioxide) because his empirical formula for it was incorrect, as atomic weights were not precisely determined until the Karlsruhe Congress. August Wilhelm von Hofmann first identified the compound as an aldehyde. He announced its production by passing methanol vapor in air over hot platinum wire. With modifications, Hofmann's method remains the basis of the modern industrial route. Solution routes to formaldehyde also entail oxidation of methanol or iodomethane.
At a meeting of the Pheu Thai Party on 20 March 2022, Paetongtarn was elected as "Head of the Pheu Thai Family". When speaking at the Pheu Thai Party's annual general meeting in April 2022, she said that she wanted to see regime change in Thailand and wanted to gain more experience before standing for the post of the country's prime minister. Paetongtarn became the leading prime minister-candidate in the opinion polls. In April 2023, she was officially nominated as one of the three prime minister-candidates of Pheu Thai Party for the general election, along with Srettha Thavisin and Chaikasem Nitisiri. After the general election in May 2023, the Pheu Thai Party secured the second-highest number of seats in the House of Representatives, following the Move Forward Party. She expressed disappointment that the party did not achieve first place as planned but stated that she was ready to work with the Move Forward Party and other parties willing to form a coalition with both parties. However, after Pheu Thai Party withdrew from the memorandum of understanding to form a government with the Move Forward Party, on 9 August, she and Pheu Thai Party executives walked from the OAI Tower, where the party's headquarters are located, to the neighbouring Thai Summit Tower to discuss with the Move Forward Party leaders about endorsing a candidate for the third round of prime ministerial voting.
Rock salt has been mined at Lake Afrera, and the surrounding part of the Afar Depression, for centuries. Lt. Lefebvre recorded some of the hazards of mining salt from the Depression, which he heard from one of the miners himself:
Sources: en.wikipedia.org
Israel started evacuating the settlements located close to the border with Lebanon in October 2023 with more than 60 thousand evacuated by April 2024. In the early afternoon of 21 October, several rockets were fired from Lebanon toward the Shebaa Farms; there were no injuries. The IDF conducted a drone strike on the team of militants that launched the rockets. A short while later, anti-tank guided missiles were fired from Lebanon toward Margaliot and Hanita; two foreign workers were injured. The IDF conducted airstrikes against the missile teams. In the evening, another anti-tank guided missile was fired from Lebanon toward Bar'am. One IDF soldier was seriously injured and two others suffered minor injuries. The IDF responded with several airstrikes in southern Lebanon, some of which targeted other missile teams preparing attacks. The IDF conducted airstrikes against two Syrian military positions on 24 October in southwestern Syria, marking the first time the IDF publicly targeted the Syrian military since the Israel–Gaza war began. Hezbollah attacked 19 IDF military sites with missiles and artillery shells and fired one-way attack drones at an IDF position for the first time since the conflict began.
==== Phosphate ceramics ==== Another way to stabilize the waste into a form that will not react or degrade for extended periods is immobilization via direct incorporation into a phosphate-based crystalline ceramic host. The diverse chemistry of phosphate ceramics under various conditions demonstrates a versatile material that can withstand chemical, thermal, and radioactive degradation over time. The properties of phosphates, particularly ceramic phosphates, of stability over a wide pH range, low porosity, and minimization of secondary waste introduces possibilities for new waste immobilization techniques.
=== General insulins === Insulins that are used mostly in humans are sometimes also used in animals such as cats and dogs. These include Lantus (insulin glargine), Novolin (NPH insulin), Humulin (NPH insulin), and Levemir (Detemir). It is of note that one of the listed insulins other than lente and PZI are FDA-approved for use in animals.
=== Snake venom === Although LAAOs are present in a variety of eukaryotic and prokaryotic organisms, snake venom is a particularly rich source of the enzyme and the LAAOs are proposed to supply toxic effects upon envenomation. LAAOs that have been purified from the venoms of various snake species have proven to be the best suitors for examining this novel family of enzymes. It has been determined in most cases concerning the snake families, such as Viperidae, Crotalidae, and Elapidae, that snake venom-LAAO (sv-LAAO) constitutes about 1%–9% of the total protein quantity.
From 1878 to 1955 the Third Avenue El ran above the Bowery, further darkening its streets, populated largely by men. "It is filled with employment agencies, cheap clothing and knickknack stores, cheap moving-picture shows, cheap lodging-houses, cheap eating-houses, cheap saloons", writers in The Century Magazine found it in 1919. "Here, too, by the thousands come sailors on shore leave, – notice the 'studios' of the tattoo artists, – and here most in evidence are the 'down and outs'". Prohibition eliminated the Bowery's numerous saloons: One Mile House, the "stately old tavern... replaced by a cheap saloon" at the southeast corner of Rivington Street, named for the battered milestone across the way, where the politicians of the East Side had made informal arrangements for the city's governance, was renovated for retail space in 1921, "obliterating all vestiges of its former appearance", The New York Times reported. Restaurant supply stores were among the businesses that had come to the Bowery, and many remain to this day. Pressure for a new name after World War I came to naught and in the 1920s and 1930s, it was an impoverished area. From the 1940s through the 1970s, the Bowery was New York City's "Skid Row," notable for "Bowery Bums" (disaffected alcoholics and homeless persons). Among those who wrote about Bowery personalities was New Yorker staff member Joseph Mitchell (1908–1996).
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.